ScholarLens Back to search
2010•Unpublished venueRequires access

CURRENT TREATMENT STRATEGY IN LANGERHANS CELL HISTIOCYTOSIS

Minkov Milen

Open publisher page 0 citations

Abstract

Langerhans cell histiocytosis (LCH) is a rare disorder described as three different entities including eosinophilic granuloma of bone, the Hand-Schuller-Christian syndrome, and Letterer-Siwe disease. LCH is currently classified into single system LCH, and multisystem LCH. Patients with single system LCH have an excellent prognosis, and are mostly treated with local therapy. Multisystem LCH is subdivided into low risk and high risk groups. A 6-week course of PRED/VBL is recommended for all patients with MS-LCH. Further therapy depends on the response to the initial course, and risk group of the patient.

About this research paper

What this paper is about

Langerhans cell histiocytosis (LCH) is a rare disorder described as three different entities including eosinophilic granuloma of bone, the Hand-Schuller-Christian syndrome, and Letterer-Siwe disease. LCH is currently classified into single system LCH, and multisystem LCH. Patients with single system LCH have an excellent prognosis, and are mostly treated with local therapy. Multisystem LCH is subdivided into low risk and high risk groups. A 6-week course of PRED/VBL is recommended for all patients with MS-LCH. Further therapy depends on the response to the initial course, and risk group of the patient.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Langerhans cell histiocytosis (LCH) is a rare disorder described as three different entities including eosinophilic granuloma of bone, the Hand-Schuller-Christian syndrome, and Letterer-Siwe disease. LCH is currently classified into single system LCH, and multisystem LCH. Patients with single system LCH have an excellent prognosis, and are mostly treated with local therapy. Multisystem LCH is subdivided into low risk and high risk groups. A 6-week course of PRED/VBL is recommended for all patients with MS-LCH. Further therapy depends on the response to the initial course, and risk group of the patient.

Key concepts: Langerhans cell histiocytosis, Eosinophilic granuloma, Medicine, Histiocytosis, Multisystem disease, Disease, Dermatology, Histiocytosis X

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
CURRENT TREATMENT STRATEGY IN LANGERHANS CELL HISTIOCYTOSIS — Research Paper | ScholarLens